DMRA · Damora Therapeutics, Inc. · Proposed Sales
$23.22
-1.08 (-4.44%)
At close · Nov 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 4, 2026
Substantial doubt about the company's ability to continue as a going concern.
“If we are unable to raise additional capital when needed, that could raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Nov 4, 2026
Market Cap
$1.44B
Shares
61.90M
Volume · Nov 20
643.39K
Avg daily vol (3M)
577.78K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Notices of intent to sell restricted or control shares, filed with the SEC on Form 144 by insiders and affiliates. A Form 144 signals a planned sale — it does not confirm the shares were actually sold.
| Filed | Seller | Relationship | Shares | Approx. Sale | Broker |
|---|---|---|---|---|---|
| 2026-08-06 | Firmani Lori | Officer | 1,800 | 2026-08-05 | Maxim Group |
| 2026-06-22 | Firmani Lori | Officer | 7,615 | 2026-06-22 | Maxim Group |
| 2023-10-02 | OrbiMed Israel Partners II, L.P. | Shareholder | 244,527 | 2023-10-02 | Merrill Lynch, Pierce, Fenner & Smith Incorporated |
| 2023-10-02 | OrbiMed Private Investments VII, LP | Shareholder | 585,274 | 2023-10-02 | Merrill Lynch, Pierce, Fenner & Smith Incorporated |
| 2023-10-02 | OrbiMed Genesis Master Fund, L.P. | Shareholder | 37,675 | 2023-10-02 | Merrill Lynch, Pierce, Fenner & Smith Incorporated |
| 2023-10-02 | The Biotech Growth Trust PLC | Shareholder | 57,312 | 2023-10-02 | Merrill Lynch, Pierce, Fenner & Smith Incorporated |
| 2023-08-30 | OrbiMed Genesis Master Fund, L.P. | Shareholder | 78,659 | 2023-08-30 | Bank of America |
| 2023-08-30 | OrbiMed Private Investments VII, LP | Shareholder | 1,222,125 | 2023-08-30 | Bank of America |
| 2023-08-30 | OrbiMed Israel Partners II, L.P. | Shareholder | 510,610 | 2023-08-30 | Bank of America |
| 2023-08-30 | The Biotech Growth Trust PLC | Shareholder | 119,679 | 2023-08-30 | Bank of America |
| 2023-08-21 | OrbiMed Genesis Master Fund, L.P. | Shareholder | 75,473 | 2023-08-15 | Bank of America |
| 2023-08-21 | OrbiMed Israel Partners II, L.P. | Shareholder | 631,048 | 2023-08-21 | Bank of America |
| 2023-08-21 | The Biotech Growth Trust PLC | Shareholder | 147,910 | 2023-08-21 | Bank of America |
| 2023-08-21 | OrbiMed Private Investments VII, LP | Shareholder | 1,510,375 | 2023-08-21 | Bank of America |
| 2023-08-15 | OrbiMed Private Investments VII, LP | Shareholder | 1,172,714 | 2023-08-15 | Bank of America |
| 2023-08-15 | The Biotech Growth Trust PLC | Shareholder | 114,843 | 2023-08-15 | Bank of America |
| 2023-08-15 | OrbiMed Israel Partners II, L.P. | Shareholder | 489,970 | 2023-08-15 | Bank of America |
| 2023-08-15 | OrbiMed Genesis Master Fund, L.P. | Shareholder | 75,473 | 2023-08-15 | Bank of America |
| 2023-07-31 | OrbiMed Genesis Master Fund, L.P. | Shareholder | 162,153 | 2023-07-31 | Bank of America |
| 2023-07-31 | OrbiMed Private Investments VII, LP | Shareholder | 930,717 | 2023-07-31 | Bank of America |
| 2023-07-31 | The Biotech Growth Trust PLC | Shareholder | 246,830 | 2023-07-31 | Bank of America |
| 2023-07-31 | OrbiMed Israel Partners II, L.P. | Shareholder | 180,300 | 2023-07-31 | Bank of America |
| 2023-07-25 | The Biotech Growth Trust PLC | Shareholder | 8,100 | 2023-07-25 | Bank of America |
| 2023-07-25 | OrbiMed Israel Partners II, L.P. | Shareholder | 4,700 | 2023-07-25 | Bank of America |
| 2023-07-25 | OrbiMed Genesis Master Fund, L.P. | Shareholder | 7,800 | 2023-07-25 | Bank of America |
| 2023-07-25 | OrbiMed Private Investments VII, LP | Shareholder | 26,700 | 2023-07-25 | Bank of America |
| 2023-07-13 | OrbiMed Private Investments VII, LP | Shareholder | 132,100 | 2023-07-13 | Bank of America |
| 2023-07-13 | The Biotech Growth Trust PLC | Shareholder | 14,700 | 2023-07-13 | Bank of America |
| 2023-07-13 | OrbiMed Genesis Master Fund, L.P. | Shareholder | 9,800 | 2023-07-13 | Bank of America |
| 2023-07-13 | OrbiMed Israel Partners II, L.P. | Shareholder | 52,800 | 2023-07-13 | Bank of America |
| 2023-04-10 | OrbiMed Israel Partners II, L.P. | Shareholder | 9,064 | 2023-04-10 | Themis Trading LLC |
| 2023-04-10 | OrbiMed Genesis Master Fund, L.P. | Shareholder | 1,686 | 2023-04-10 | Themis Trading LLC |
| 2023-04-10 | The Biotech Growth Trust PLC | Shareholder | 2,512 | 2023-04-10 | Themis Trading LLC |
| 2023-04-10 | OrbiMed Private Investments VII, LP | Shareholder | 22,638 | 2023-04-10 | Themis Trading LLC |
| 2023-04-05 | OrbiMed Private Investments VII, LP | Shareholder | 109,532 | 2023-04-05 | Themis Trading LLC |
| 2023-04-05 | OrbiMed Genesis Master Fund, L.P. | Shareholder | 8,143 | 2023-04-05 | Themis Trading LLC |
| 2023-04-05 | OrbiMed Israel Partners II, L.P. | Shareholder | 43,810 | 2023-04-05 | Themis Trading LLC |
| 2023-04-05 | The Biotech Growth Trust PLC | Shareholder | 12,215 | 2023-04-05 | Themis Trading LLC |
Showing 1–38 of 38 filings
Key facts
CIK
1800315
CUSIP
G2646Y104
13F (30d)
115 filings
112 filers
Visit website
Investor relations